Advancing research, development and therapy for ALS and additional CNS indications.
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) is a clinical stage Biotech company focusing on the development of a ground-breaking treatment for ALS patients, as well as other neurodegenerative diseases.
Currently in conducting a Phase 2b, double-blind, randomized, placebo controlled clinical study in ALS patients globally.
$NRSN
Company Details
- Employees
- 31
- Founded
- -
- Address
- 1 Broadway, Cambridge,massachusetts 02142,united States
- Phone
- +972-9-9531142
- in****@****-tx.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- neurosense-tx.com
- Keywords
- Drug Development, ALS, MND, Lou Gehrig's Disease, CNS, Biopharmaceuticals, Neurodegenerative Diseases, Parkinson's Disease, Alzheimer's disease, Novel treatment.
- HQ
- Cambridge, Massachusetts
Neurosense Therapeutics Questions
Neurosense Therapeutics's helpline number is +972-9-9531142
Neurosense Therapeutics's website is neurosense-tx.com
Neurosense Therapeutics's LinkedIn profile is https://www.linkedin.com/company/neurosense-therapeutics
Neurosense Therapeutics has
31 employees.
View email and phone details for 31
employees at Neurosense Therapeutics.
Neurosense Therapeutics's industry is
Biotechnology Research
Neurosense Therapeutics's top competitors are
Brain.q,
Brainstorm Cell Therapeutics,
Quantalx Neuroscience Ltd,
Evogene,
Anima Biotech,
Cytoreason,
Neurokaire (Formerly Genetika+),
Clene Nanomedicine, Inc.,
Biolinerx,
Prilenia.
Neurosense Therapeutics's support email address is info@neurosense-tx.com
Neurosense Therapeutics's categories are Biotechnology Research
Neurosense Therapeutics's founding year is 2017
